Category: 90326-61-7

Marzin, Adolf published an article in 1933, the title of the article was 2,5-Dibromotoluic acid.Computed Properties of 90326-61-7 And the article contains the following content:

2,5,4-Br2MeC6H2CO2H, m. 195°, NaOH and MeOH, refluxed 8 days, give 45-50% of 5-bromo-2-methoxy-p-toluic acid (I), m. 130-3°; with HI there is a quant. yield of 5-bromo-4-methylsalicylic acid, m. 205-8°. Oxidation of I with alk. KMnO4 gives 5-bromo-2-methoxyterephthalic acid, m. 265-8°; HI gives the 2-HO derivative, pale yellow, which gives a deep blue-red color with FeCl3. 2,5-Dibromoterephthalic acid and AcONa give about 90% of the 2,5-di-HO derivative, m. above 300°. The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).Computed Properties of 90326-61-7

5-Bromo-2-methoxy-4-methylbenzoic acid(cas:90326-61-7) belongs to organobromine compounds. Most organobromine compounds, like most organohalide compounds, are relatively nonpolar. Bromine is more electronegative than carbon (2.9 vs 2.5). Consequently, the carbon in a carbon–bromine bond is electrophilic, i.e. alkyl bromides are alkylating agents. Computed Properties of 90326-61-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Julia, Marc; Chastrette, Francine published an article in 1962, the title of the article was 4-Substituted salicyclic acids.HPLC of Formula: 90326-61-7 And the article contains the following content:

The preparation of 4,3-HO2C(HO)C6H3(CH2)nCO2H (I) (n = 1, 2, 3) is described. m-AcOC6H4Me (600 g.) and 600 cc. powd. AlCl3 heated at 120-65° and steam distilled, and the distillate extracted with Et2O gave 470 g. 4,2-Me(HO)C6H3Ac (II), b0.6 82-4°, n2D4 1.5542; semicarbazone m. 218-20° (EtOH). II (167 g.) in 500 cc. aqueous NaOH heated 6 h. on a steam bath with 140 g. Me2SO4, treated again with 470 g. Me2SO4 and with a sufficient amount aqueous NaOH to maintain alkalinity, and extracted with Et2O yielded 180 g. 4,2-Me(MeO)C6H3Ac (III), b0.6 100-3°, m. 35-6°; semicarbazone m. 194-8°. III (192 g.) and 4.1 l. 1.4N NaOCl, 2.3-2.6N in NaOH, stirred several hrs., treated with aqueous NaHSO3, and acidified with concentrated HCl precipitated 184 g. 4,2-Me(MeO)C6H3CO2H (IV), m. 103-4° (aqueous EtOH). III (48 g.) treated with 900 cc. 1.7N NaOCl, 3.14N in NaOH, yielded 53 g. 3,5,4,2-Cl2Me(MeO)C6-H6CO2H, m. 175-6°. IV (93 g.), 900 cc. absolute MeOH, and 6 g. concentrated H2SO4 refluxed overnight, the mixture concentrated, poured onto ice, and extracted with Et2O gave 75 g. 4,2-Me(MeO)C6H3CO2Me (V), b22 142°, m. 29°, n1D8 1.5230. V (4.5 g.) in 100 cc. AcOH treated dropwise with 4.5 g. Br, the mixture stirred 3 h., kept overnight, diluted with H2O, and extracted with Et2O yielded 5.4 g. Me ester (VI) of 5,4,2-BrMe(MeO)C6H2CO2H (VII), m. 46°. VI saponified gave VII, m. 134-5°. IV (2.2 g.) in 40 cc. CCl4 refluxed and irradiated (W filament) with stirring, treated during 1 h. with 2.2 g. Br, heated 2 h., stirred 12 h., and filtered gave 2.44 g. VII, m. 135° (C6H6). VII (6.2 g.) in 90 cc. 95% EtOH and 30 g. Raney Ni-Al alloy treated dropwise with 300 cc. 10% aqueous NaOH, refluxed 1 h., and filtered, the filtrate added to 250 cc. concentrated HCl, the precipitate extracted with C6H6, and the extract evaporated yielded 3.66 g. IV, m. 102°. N-Bromosuccinimide (2.5 g.), 3.6 g. Bz2O2, 30 g. V, and 75 cc. CCl4 refluxed 3 h., cooled, filtered, and distilled gave 7 g. unchanged V and 26 g. oil, b0.03 122-42°, which, fractionally recrystallized from MeOH and petr. ether, gave 4 g. VI and 8 g. 4,2BrCH2(MeO)C6H3CO2Me (VIII), m. 51°. VIII (4 g.) and 3.2 g. (CH2)6N4 in 30 cc. CHCl3 refluxed I hr. and filtered, the residue refluxed 2 h. with 50 cc. AcOH and 50 cc. H2O, poured into H2O, and extracted with Et2O, and the extract worked up gave 1.5 g. oily 4,3-MeO2C(MeO)C6H3CHO; 2,4-dinitrophenylhydrazone m. 228-30° (C6H6). VIII (4 g.) in 100 cc. EtOH treated dropwise with stirring with 1.1 g. KCN in 50 cc. H2O, kept 4 h. at room temperature, refrigerated 14 h., diluted with saturated aqueous NaCl, and extracted with Et2O gave 1.77 g. 4,3-MeO2C(MeO)C6H3CH2CN, b0.3 149-50° m. 59-60°(EtOH). 4,2-Me(MeO)C6H3CO2H (20 g.) in 300 cc. dry CCl4 refluxed and irradiated as above with stirring, treated with a small amount powd. AlCl3 and a few cc. solution of 2.14 g. Br in 120 cc. CCl4, the mixture then treated dropwise during 17-20 h. with the remainder of the Br solution, kept overnight at room temperature, and several hrs. at 0°, and filtered yielded 15-16 g. 4,3-HO2C(MeO)C6H3CH2Br (IX), m. 124-5° (C6H6). IX (12 g.) stirred 3 h. at 0° with 110 cc. saturated HCl-MeOH, refrigerated overnight, diluted with ice, washed with Et2O, neutralized with solid NaHCO3, and extracted with Et2O gave 10 g. VIII, m. 51°. IX (500 mg.) and 500 mg. NaOAc in 5 cc. AcOH refluxed 2 h., diluted with H2O, and filtered yielded 330 mg. 4,3-HO2C(MeO)C6H3CHOAc, m. 100°. IX (5 g.) neutralized with 2N NaOH, treated gradually with 2 g. KCN, the mixture stirred 2 h. at room temperature, acidified, extracted with CHCl3, and the oily product chromatographed on silica gel yielded 64% 4,3-HO2C(MeO)C6H3CH2CN (X), m. 113-15° (C6H6-ligroine, b. 60-80°). X (1 g.) refluxed 2 h. with 10 cc. aqueous NaOH and 2 cc. EtOH, acidified, and filtered yielded 77% 4,3HO2C(MeO)C6H3CH2-CO2H (XI), m. 137.5-39° (Et2O-petr. ether). XI (1 g.), 2 cc. AcOH, and 2 cc. 48% HBr refluxed 1 h. and cooled gave 0.75 g. I (n = 1), m. 208-10° (H2O). 4,3-NC(O2N)C-6H3Me (XII) (10 g.) treated with Cl during 8.5 h. at 120-30° with irradiation with UV light, cooled, and filtered, and the residue triturated with cold EtOH gave 5 g. crude unreacted XII; the oily residue from the extract refluxed 2 h. with KOAc-AcOH, cooled, poured into H2O, extracted with Et2O, and the oily residue from the extract chromatographed on Al2O3 gave successively 10% oil, 43% unreacted XII, 5% oil, and 20% 4,3-NC(O2N)C6H3CH2OAc (XIII), m. 64-4.5°. XII (7 g.), 0.5 g. Bz2O2, and 45 cc. CCl4 refluxed 67 h. with 8 g. N-bromosuccinimide, filtered, and worked up, and the oily product (1.2 g.) refluxed 2 h. with KOAc-AcOH yielded 32% XIII, m. 64-5°. XII (25 g.) treated at 150° (later at 120-5°) with 3.3 g. Br with UV irradiation during 7 h. and extracted with Et2O, and the oily residue (32.5 g.) from the extract refluxed 2 h. with KOAc-AcOH yielded 25-30% XIII. Similarly were prepared the benzoate analog (XIV), m. 138-9.5° (C6H6), and the p-nitrobenzoate (XV) analog of XIII, m. 168.570° (CHCl3-C6H6). XIII, XIV, and XV treated overnight with an equivalent amount 50% aqueous KOH in 50-100 volume absolute EtOH at 0° yielded 80% 4,3-NC(O2N)C-6H3CH2OH, m. 78.5-80.5° (C6H6ligroine). 3,4-MeO(O2N)C-6H3Me (XVI) (1.8 g.) in 20 cc. CCl4 refluxed 4-5 h. with 4 cc. Br, bubbled with N, cooled, and filtered gave 2.1 g. 6,3,4-Br(MeO)-(O2N)C6H3Me. XVI (5 g.), 5.4 g. N-bromosuccinimide, and 0.3 g. Bz2O2 refluxed overnight in 30 cc. CCl4 (addnl. Bz2O2 was added after 4 h.) gave 58% 3,4-MeO(O2N)C6H3CH2Br (XVII), m. 97-820 (C6H6-ligroine). XVII (230 mg.), 230 mg. KOAc, and 5 cc. AcOH refluxed 1 h. yielded 175 mg. 3,4-MeO(O2N)C6-H3CH2OAc, m. 61-3° (C6-H6petr. ether). XVII (4 g.), 3.5 g. (CH2)-6N4, and 30 cc. CHCl3 refluxed 4 h., cooled, and filtered, and the residue (5.5-6.0 g.) refluxed 2 h. with 45 cc. AcOH and 45 cc. H2O, cooled, poured onto ice, and extracted with Et2O yielded 1.1-1.6 g. yellow 3,4-MeO-(O2N)C6H3CHO, m. 97-9° (EtOH); 2,4-dinitrophenylhydrazone m. 279-80° (EtOAc). X (1.05 g.) in 30 cc. Ac2O hydrogenated over 200 mg. PtO2, centrifuged, and evaporated, and the oily residue refluxed 4 h. with 2 cc. AcOH and 2 cc. 48% HBr and filtered gave 0.7 g. 4,2H2NCH2CH2(HO)C6-H3CO2H.HBr, m. 260° (absolute EtOH-Et2O). Hydrated Na2S (25.7 g.), 10.7 g. sulfur flowers, 23 g. KOH pellets, and 51 cc. H2O heated 15 min. on a water bath, added to 35 g. XVI in 260 cc. 95% EtOH, refluxed 4 h., steam distilled, and the distilled oil stirred several hrs. at 0° and filtered gave 13.6 g. 4,3-H2-N(MeO)C6H3CHO (XVIII), m. 100°; the gummy residue from the filtrate dissolved twice in saturated aqueous NaHSO3 and treated with 5N NaOH gave an addnl. 7.8 g. XVIII. XVIII (12 g.), 60 cc. AcOH, 10 cc. Ac2O, and 6 g. NaOAc refluxed 1.5 h., poured onto ice, saturated with Na2CO3, and filtered gave 15.3 g. 4,3-AcNH(MeO)C6H-3CHO (XIX), m. 142-5°. XIX (18.5 g.) in 23.5 cc. C5H5N, 10 g. CH2(CO-2H)2, and 1 cc. piperidine heated 5 h. on a water bath, cooled, poured onto 300 cc. ice and 30 cc. AcOH, and filtered yielded 75% 4,3-AcNH(MeO)C6H3CH:CHCO2H (XX), m. 213° (decomposition)(EtOH). XX (5.0 g.) in 30 cc. H2O shaken 1 h. with Na-Hg from 1.32 g. Na and 72 g. Hg, filtered, and acidified yielded 4.4 g. 4,3-AcNH(MeO)-C6H3CH2CH2CO-2H (XXI), m. 112° (H2O). XXI (6 g.) and 10 cc. solution of 8.8 g. KOH in 6.3 cc. H2O, diluted with MeOH to 25 cc., heated 1 h. on a water bath, treated with 5.5 cc. H2O, heated again 0.5 h., neutralized with HCl, and filtered gave 4.8 g. 4,3-H2N(MeO)C6H3CH2CH2CO2H (XXII), m. 98-9° (C6H6-ligroine). XXII (5 g.) neutralized with 2.7 g. Na2CO3 in 20 cc. H2O, treated with cooling with 2 g. NaNO2 in 10 cc. H2O, added with stirring and cooling to 10.5 cc. concentrated HCl and 10.5 cc. H2O at 6-8°, poured at 50-60° to a solution of CuCN from 6 g. CuSO4, 7.5 g.. KCN, and 30 cc. H2O, stirred 1 h. at 60-70°, filtered, acidified, and extracted with CHCl-3 yielded 2.9-3.15 g. 4,3-NC(MeO)C6H-3CH2CH2CO2H (XXIII), m. 159-60° (C6H6-ligroine). XXIII (0.5 g.), 1 cc. AcOH, and 1 cc. 48% HBr refluxed overnight and filtered gave 0.27 g. I (n = 2), m. 230° (decomposition) (EtOH). XVI (20 g.), 500 cc. H2O, and 45 g. KMnO4 refluxed until decolorized, treated during 6 h. at 0.5-h. intervals with 5-g. portions KMnO4, filtered hot, concentrated to 250 cc., and acidified with concentrated HCl gave 20-2 g. 3,4-MeO(O2N)C6H3CO2H (XXIV), m. 230.5°. XXIV (25 g.) and 50 cc. SOCl2 refluxed 4 h. and distilled yielded 22 g. 3,4-MeO(O2N)C6H3COCl (XXV), b1 150-60°, m. 50-5°. Mg (5.85 g.), 37 cc. absolute EtOH, and 1 cc. dry CCl4 treated with stirring with 37 cc. dry PhCl and then during 4 h. with coolingwith 26.4 cc. CH2(CO2Et)-2 and 18 cc. PhCl in 80 cc. absolute EtOH below 65°, heated slowly to 85°, kept about 2 h. at 85°, cooled to 25°, treated slowly with 32 g. XXV in 93 cc. PhCl with stirring below 35°, stirred 0.5 h. at 35°, and treated with cooling with 9.3 cc. H2SO4 > in 65 cc. H2O, the organic phase decanted, dried, and evaporated, and the residue refluxed 6 h. with 5 cc. AcOH, 6.5 cc. H2SO4, and 35 cc. H2O, cooled, and poured onto ice gave 19.5 g. 3,4-MeO(O2N)C6H3Ac (XXVI), m. 72-3° (ligroine); 15% unreacted XXV was recovered. XXVI (2 g.) in 5 cc. AcOH treated slowly with 1.64 g. Br in 5 cc. AcOH, diluted wi h H2O, and filtered yielded 2.5 g. 3,4-MeO(O2N)C6H3COCH2Br (XXVII), m. 90-1.5° (EtOH). NaH (250 mg.) and 3.1 cc. CH2(CO2Et)2 in 25 cc. HCONMe2 stirred until H evolution ceased, stirred an addnl. 0.5 h., treated with 2.74 g. XXVII in 30 cc. HCONM 2, stirred 23 h. at room temperature, evaporated in vacuo, and the residual oil triturated with a little Et2O gave 1.3 g. 3,4-MeO(O2N)C6H-3COCH2CH(CO2Et)2, m. 78-80° (EtOH), which upon acid or alk. hydrolysis gave only gummy products. EtO2CCHAcCH CO2Et (XXVIII)(15.5 g.) and 1.65 g. powd. Na in 105 cc. C6H6 refluxed 2 h., treated slowly with 15 g. 3,4-MeO(O2N)C6H3C ,Cl in 45 cc. C6H6, heated 1 h. on a water bath, kept 24 h., filtered, evaporated, the residue dissolved in 100 cc. Et2O, filtered, worked up, and the viscous oily product heated with occasional shaking on a water bath with 110 cc. 70 % H2SO4, cooled, filtered, and poured into ice gave 5.8 g. 3,4-MeO(O2N)C6H3CO-CH2CH-2CO2H (XXIX), m. 137-8.5° (H2O). XXVIII treated in the usual manner with 1 g. 3,4-MeO(O2N)C6H3COCl yielded 34% 3,4-MeO(O2N)C6H3COCAc(CO-2Me)CH2CO2Me, m. 99-100.5° (Et2O-petr. ether). XXIX (32.4 g.) in 145 cc. 2N NH4OH added at room temperature to 208 g. FeSO-4.5H2O in 340 cc. H2O, basified with 10% NH4OH, boiled a few min., filtered, concentrated to about 800 cc., adjusted with concentrated HCl to pH 6, and filtered gave 23 g. 4,3-H2N(MeO)C6-H3COCH2CH2CO2H (XXX), m. 152-3° (H2O). XXX (22.5 g.) and 10.3 g. Na2CO3 in 60 cc. H2O treated with stirring and cooling with 7.9 g. NaNO2 in 70 cc. H2O and then slowly with cold 52 cc. concentrated HCl and 52 cc. H2O below 4° added to CuCN solution from 23.4 g. CuSO4 and 29.3 g. KCN in 175 cc. H2O, heated 1 h. at 70° cooled, and acidified yielded 14.4 g. 4,3-NC(MeO)C6-H3COCH2CH2CO2H (XXXI), m. 153-4° (CHCl3). XXXI (14 g.), 104 cc. 10% aqueous NaOH, and 28 cc. 95% EtOH refluxed 2.5 h. under N, cooled, acidified with concentrated HCl, and extracted with CHCl3 yielded 10.6 g. 4,3-HO2C-(MeO)C6H3COCH2CH2CO2H (XXXII), m. 158-9.5° (CHCl3-ligroine). XXXII (10.6 g.), 60 cc.(HOCH2CH2)-2O, 8 g. KOH pellets, and 10 cc. 95% N2H4.H2O refluxed 2 h., distilled to 145-50° pot temperature, refluxed 5 h., cooled, acidified with concentrated HCl, extracted with CHCl3, and the crude oily product (6.7 g.) chromatographed on silica gel yielded 2.38 g. 4,3-HO2C(MeO)C-6H3(CH2)3CO2H (XXXIII), m. 110-12° (C6H6-ligroine). XXXIII (2.5 g.) heated 1 h. on a water bath with 5 cc. AcOH and 5 cc. 48% HBr yielded 1.1g. I(n = 3), m.205-° (H2O). XXXI (200 mg.), 0.4 cc. AcOH, and 0.4 cc. 48% HBr refluxed overnight gave 15 mg. 4,3-HO2C(HO)C6H3COCH2CH-2CO2H, m. 211-14° (H2O). The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).HPLC of Formula: 90326-61-7

5-Bromo-2-methoxy-4-methylbenzoic acid(cas:90326-61-7) belongs to organobromine compounds. Most organobromine compounds, like most organohalide compounds, are relatively nonpolar. Bromine is more electronegative than carbon (2.9 vs 2.5). Consequently, the carbon in a carbon–bromine bond is electrophilic, i.e. alkyl bromides are alkylating agents. HPLC of Formula: 90326-61-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On November 7, 2019, Wang, Guoqiang; Shen, Ruichao; Granger, Brett; He, Jing; Xing, Xuechao; He, Yong; Long, Jiang; Ma, Jun; Wang, Bin; Or, Yat Sun published a patent.COA of Formula: C9H9BrO3 The title of the patent was Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof. And the patent contained the following:

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: I which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-l associated with hepatic steatosis, including non-alc. fatty liver disease (NAFLD) and non-alc. steatohepatitis (NASH). The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).COA of Formula: C9H9BrO3

The Article related to tetrazole apoptosis signal regulating kinase 1 inhibitors nafld nash, ask1 mediated liver kidney autoimmune neurodegenerative inflammatory cardiovascular diseases, Pharmacology: Drug Interactions and General Pharmacology and other aspects.COA of Formula: C9H9BrO3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 1, 2020, Komandla, Mallareddy; Miura, Joanne; Wang, Haixia; Wang, Xiaolun; Lawson, John David; Tyhonas, John published a patent.COA of Formula: C9H9BrO3 The title of the patent was 2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-6-yl)-4-methylbenzamide derivatives and related heterocycles as RIPK2 inhibitors for the treatment of autoimmune and other diseases. And the patent contained the following:

The invention relates to preparation of dihydroimidazopyridine benzamides(I) and related heterocycles, and pharmaceutically acceptable salts thereof, as RIPK2 inhibitors. Compounds I wherein α is a single bond; β is a double bond; R2 is oxo; R3 is C1-6 alkyl; R4, R5, R6, R7 and R8 each independently is H, halo, C1-4 alkyl, etc.; R9 is C1-6 alkyl, C3-8 haloalkyl, C2-8 heteroalkyl, etc.; etc., are claimed. The example compound II was prepared from the intermediates(also prepared), (procedure given). Compounds I were evaluated for their biol. activities (data given). Compounds I are receptor-interacting protein kinase 2 (RIPK2) inhibitors and can be useful for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren’s syndrome, ankylosing spondylitis, Behcet’s disease, graft vs. host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).COA of Formula: C9H9BrO3

The Article related to dihydroimidazopyridine benzamide preparation ripk2 inhibitor autoimmune disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.COA of Formula: C9H9BrO3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 15, 2011, Yeung, Kap-Sun; Parcella, Kyle E.; Bender, John A.; Beno, Brett R.; Grant-Young, Katharine A.; Han, Ying; Hewawasam, Piyasena; Kadow, John F.; Nickel, Andrew published a patent.Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid The title of the patent was Preparation of benzofurancarboxamide derivatives and their preparation and use for the treatment of hepatitis C. And the patent contained the following:

The invention relates to benzofurancarboxamide derivatives of formula I, which are useful for treatment of hepatitis C. Compounds of formula I wherein R1 is NR5R6, alkoxy, Ph, etc.; R2 is H, halo, NO2, NH2, Ph and NR5R6; R3 is CN, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, etc.; R4 is substituted Ph; R5 is H, alkyl and alkylsulfonyl; R6 is H, alkyl, hydroxyalkyl, alkoxyalkyl and alkylsulfonyl; R20 and R21 are independently H, halo, alkyl and alkoxy; and pharmaceutically acceptable salts thereof, are disclosed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their activity against HCV. From the assay, it was determined that compound II exhibited IC50 and EC50 values in the range 0.002 – 0.25 μM, resp. The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid

The Article related to benzofurancarboxamide preparation treatment hepatitis c, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenofurans and other aspects.Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 6, 1999, Thompson, Mervyn; Harling, John David; Edwards, Peter David published a patent.Product Details of 90326-61-7 The title of the patent was Preparation of substituted isoquinolines as anticonvulsants. And the patent contained the following:

The title compounds [I; n, p = 1-4 and n + p = 2-5; R1 = H, cycloalkylO, etc.; R2 = H, halo, CN, etc.; R3 = H, halo, NO2, etc.; R2R3 = (un)substituted (un)saturated carbocyclic ring; R4 = H, alkyl, alkenyl, etc.], useful as anticonvulsants, were prepared Thus, conversion of 2-ethoxy-4-isopropyl-5-cyanobenzoic acid into the acid chloride followed by coupling with 5-amino-2-methyl-1,2,3,4-tetrahydroisoquinoline afforded 60% II.HCl which showed a 336% increase in seizure threshold for rat MEST. Compounds I are useful in the prophylaxis and treatment of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid hemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc. and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson’s disease, psychosis, migraine, cerebral ischemia, Alzheimer’s disease and other degenerative diseases such as Huntington’s chorea, schizophrenia, obsessive compulsive disorders (OCD), neurol. deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Giles de la Tourette’s syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS). The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).Product Details of 90326-61-7

The Article related to isoquinoline preparation anticonvulsant, anxiolytic isoquinoline preparation, antidepressant isoquinoline preparation, substance abuse isoquinoline preparation, parkinson disease isoquinoline preparation, alzheimer disease isoquinoline preparation, antipsychotic isoquinoline preparation, huntington chorea isoquinoline preparation and other aspects.Product Details of 90326-61-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary